Guolian Securities released a research report on April 27 stating that it gave Mike Biotech (300463.SZ) a purchase rating, and the target price was 15.10 yuan. The main reasons for the rating include: 1) the installed performance of the assembly line is impressive, which is expected to drive the increase in reagents in the future; 2) the profit side is under pressure in the short term due to increased marketing efforts. (Mainichi Keizai Shimbun)
国联证券4月27日发布研报称，给予迈克生物（300463.SZ）买入评级，目标价格为15.10元。评级理由主要包括：1）流水线装机表现亮眼，后续有望带动试剂上量；2）市场推广力度加大致利润端短期承压。（每日经济新闻）
Guolian Securities released a research report on April 27 stating that it gave Mike Biotech (300463.SZ) a purchase rating, and the target price was 15.10 yuan. The main reasons for the rating include: 1) the installed performance of the assembly line is i
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.